Bone Morphogenetic Protein Receptor Type II (BMPR2) Gene Mutation Analysis
The bone morphogenetic protein receptor type II (BMPR2) gene located on chromosome 2q33.2 is responsible for synthesis of protein called bone morphogenetic protein receptor type 2 (BMPR-II). BMPR-II as a serine/threonine receptor kinase belonging to the transforming growth factor β (TGF-β) cell–signaling superfamily responsible for regulating cell growth and differentiation. As its name implies, the original role of the BMPR-II was in regulating the growth and maturation (differentiation) of bone and cartilage; however, recent research has shown that mutations on the BMRP2 gene is closely associated with pulmonary arterial hypertension (PAH) as it inhibits the proliferation of vascular smooth muscle tissue. When its function is impaired due to gene mutations, vascular smooth muscle proliferates resulting in thickening of pulmonary blood vessels leading to pulmonary hypertension. Affected patients may develop cor-pulmonale, a condition that causes the right side of the heart to fail. In addition, it has been shown that BMRP-II through TGF-β can upregulated elastic fibers resulting in pulmonary fibrosis.
PAH is defined as the presence of an abnormally elevated pulmonary arterial pressure. PAH can be idiopathic, heritable, drug- or toxin-induced, or caused by associated conditions, such as HIV infection, congenital heart diseases, portal hypertension, schistosomiasis, and connective tissue diseases. Management of PAH is important as it can result to complications including right ventricular dysfunction/right heart failure, peripheral edema, ascites, and tachyarrhythmias. Therefore, screening for BMPR2 mutations in relatives of patients with idiopathic pulmonary hypertension is important as these mutations are present in >70% of familial cases. In addition, gene mutation analysis including analysis for gene deletions and duplications may be of benefit in the diagnosis of PAH.
- As an aid in diagnosis of pulmonary arterial hypertension
- Screening for BMPR2 mutations in relatives of patients with idiopathic and or familiar pulmonary hypertension
Negative for mutations analyze (No mutation detected)
Whole blood (EDTA).
Stability
- Ambient: 7 days
- Refrigerated: 7-14 days
- Chest. 2004 Jul;126(1 Suppl):14S-34S. [PMID: 15249493]
- BMC Med Genet. 2017 Aug 2; 18(1):82. [PMID: 28768485]
- Curr Hypertens Rep. 2015 Mar; 17(3):20. [PMID: 2575431]
- Respiration. 2007;74(2):123-32. [PMID: 17318011]
- Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1559-1569. [PMID: 28619995]
- Am J Cardiol. 2012 Aug 15; 110(4):586-93. [PMID: 22632830]
- Biol Sex Differ. 2012 Feb 20; 3(1):6. [PMID: 22348410]
- Am J Respir Crit Care Med. 2010 Nov 1; 182(9):1153-60. [PMID: 20581168]
- Am J Respir Crit Care Med. 2006 Sep 1; 174(5):590-8. [PMID: 16728714]
- Hum Mutat. 2006 Feb; 27(2):212-3. [PMID: 16429403]
- Eur Respir J. 2004 Mar; 23(3):373-7. [PMID: 15065824]
- Lancet. 2003 May 3; 361(9368):1533-44. [PMID: 12737878]